AbbVie Inc (BUE:ABBV)
ARS 21100 275 (1.32%) Market Cap: 326.28 Til Enterprise Value: 391.76 Til PE Ratio: 63.33 PB Ratio: 53.42 GF Score: 74/100

AbbVie Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 03:00PM GMT
Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

I think we're going to get started. Good morning, everybody. Thanks for joining us. I'm Terence Flynn, the biopharma analyst here at Goldman Sachs. We're very pleased to have AbbVie with us this morning. Joining us from their company, we have Mike Severino, Vice Chairman and President; and Rob Michael, Senior Vice President and CFO. Thanks very much for joining us.

Now Before we get started, after I read the disclaimer. We are required to make certain disclosures in public appearances about Goldman Sachs' relationships with companies that we discuss. These disclosures relate to investment banking relationships, compensation received or 1% or more ownership. We're prepared to read aloud disclosures for any issuer upon request. However, these disclosures are available in our most recent reports available to U.S. clients on our firm portals. Disclosures and updates to these disclosures are also available by ticker on the firm's public website at www.gs.com. Also the views

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot